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Summary 
T cell receptor recognition of antigen can lead either to T lymphocyte differentiation and proliferation 
or to a state of unresponsiveness, which is dependent on whether appropriate costimulatory signals 
are provided to the mature T  cell. We have investigated a novel intracellular signaling pathway 
provided by the costimulatory molecule CD28.  CD28 engagement triggers the activation of 
an acidic sphingomyelinase (A-SMase), which results in the generation of ceramide, an important 
lipid messenger intc~i~ediate.  A-SMase activation by CD28 occurred in resting as well as in activated 
primary T  cells or leukemic Jurkat cells.  In contrast, ligation of either CD3 or CD2 did not 
result in A-SMase activation. Overexpression of recombinant A-SMase in Jurkat T cells substituted 
for CD28 with regard to nuclear factor-gB activation. These data suggest that CD28 provides 
an important costimulatory signal by activation of an acidic sphingomyelinase pathway. 
T 
he generation of an adaptive immune response requires 
the activation of naive lymphocytes that recognize an- 
tigens with their specific receptors. However, triggering of 
the antigen-specific receptor (TCR) alone appears to be in- 
sufficient to activate effector cells and only provides an in- 
complete stimulatory signal (1, 2). In vitro and in vivo studies 
of T  cell activation have demonstrated that additional cell- 
associated ligands play a key function during the initial phase. 
Some of these ligands function to stabilize the physical inter- 
action of the APC and the T  cell (3-5), but others provide 
important costimulatory signals that are crucial for complete 
activation (1,  6-8). 
Costimulatory molecules induce separate signals that com- 
plement TCR function. TCR complex-initiated signal cas- 
cades comprise cytoplasmic protein tyrosine kinases such as 
members of the src family (lck, fyn) and the syk/ZAP-70 
family as well as protein tyrosine phosphatases such as CD45 
(9-18). The CD28 costimulatory signaling is only beginning 
to be understood (for review see references 19 and 20). The 
physiological ligands for CD28, B7-1, and B7-2, have been 
identified as cell-surface molecules expressed by APC (21-25). 
B7-1 through binding to CD28 can increase cellular tyrosine 
phosphorylation and activate phosphatidylinositol 3-kinase 
(PI  3-kinase) 1 (26,  27).  Other  early  signal  transduction 
events observed after CD28 ligation include activation of phos- 
pholipase C3,1  (28),  raf-1  kinase (29),  p21  r~s (30),  and in- 
crease  of Ca 2+  and inositol  (1,  4,  5)  P3  (28,  31).  Recent 
studies have shown that CD28 itself becomes phosphorylated 
at Try191, which is essential for the interaction with the p85 
subunit of PI 3-kinase (26,  27).  While TCR activation of 
tyrosine kinases leads to CD28 Tyr191 phosphorylation, the 
identity of the kinase that phosphorylates CD28 remains un- 
known. It has been recently proposed that at least two sig- 
naling pathways are coupled to CD28 depending on the de- 
gree  of  CD28  phosphorylation  and  the  state  of cellular 
activation (20). This model reconciles previously noted dis- 
crepancies of CD28 signal transfer reactions observed with 
resting T  cells versus T  cell blasts or transformed T  cells. 
It remains to be shown, however, which of these CD28 sig- 
naling pathways functions as a costimulatory signal for the 
TCR complex. 
Costimulatory signals are required for expression of the 
high affinity IL-2 receptor, IL-2 production, and a prolifera- 
tive T cell response (1, 2, 8, 32, 33). These events are greatly 
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pression subsequent to the targeted disruption of the CD28 
gene (34). It has been shown that TCR and CD28 stimula- 
tion together lead to the activation of the nuclear factor-KB 
(NF-xB), which has been directly implicated in the transcrip- 
tion of the IL-2 and the IL-2 receptor oe gene (8,  35-37). 
Recently, we have shown that the TNF-dependent activa- 
tion of NF-xB is mediated via an acidic sphingomyelinase 
A (A-SMase) (38, 39). This enzyme catalyzes the breakdown 
of sphingomyelin to phosphorylcholine and ceramide that 
eventually triggers the proteolytic degradation of I-KB re- 
quired for the subsequent nuclear translocation of NF-Kb (39, 
40). These observations prompted us to investigate whether 
the A-SMase is also involved in the CD28 signal pathway 
of NF-KB activation. 
Here we show that CD28 triggers A-SMase activation in 
resting as well as in activated T cells. In contrast, A-SMase 
is not activated by CD3 ligation. Overexpression of recom- 
binant A-SMase is shown to substitute for CD28 in the NF- 
xB activation pathway. Evidence  is provided that A-SMase 
triggering by CD28 may represent  an important costimula- 
tory signal  for T  cell activation. 
Materials  and Methods 
Cell Culture and Reagents.  The basic culture media consisted 
of a mixture  of Click's/R.PMI 1640 (50%/50%  vol/vol) sup- 
plemented with 5%  FCS, 2 mM glutamine, 0.1  mM mercap- 
toethanol, and 50 #g/ml each of penicillin and streptomycin. The 
human acute leukemic  T cell line  Jurkat (obtained from the Amer- 
ican Type Culture Collection, Rockville, MD) was maintained in 
culture medium in a humidified incubator containing 5% COs. 
Hamster mAb IgG anti-murine CD28 clone 37.51 was obtained 
from PharMingen (San Diego, CA), and hamster mAb anti-mu- 
rine CD3 (hybridoma 145-2Cll) was kindly provided by Dr. J. 
Bluestone (Ben May Institute, University  of  Chicago, Chicago, IL). 
Murine IgG1 mAb anti-human CD2 (clone  6F10.3), murine IgG2a 
mAb anti-human CD3 (clone  X35), routine mAb IgG1 anti-human 
CD28 clone 28.2, rabbit IgG anti-hamster F(ab)z fragment cross- 
linking Ab, and goat IgG (H+L) anti-murine  cross-linking Ab 
were obtained from Dianova (Hamburg, Germany). 
Highly purified recombinant TNF-ol was kindly provided by 
Dr.  G.  Adolf, Boehringer Research Institute,  Vienna, Austria. 
Monensin, chloroquine, B-glycerophosphate,  p-nitrophenyl phos- 
phate, leupeptin, pepstatin, and trypsin-chymotrypsin  inhibitor were 
obtained from Sigma Chemical Co. (St. Louis, MO). [N-methyl- 
~C]sphingomyelin from bovine origin was obtained from Amer- 
sham International (Braunschweig, Germany). 
Inbred BALB/c mice were obtained from Bomholtgard (Rye, 
Denmark). Mice of both sexes ranging in age from 6 to 10 wk 
old were used. 
Preparation ofPen'pheral T Cells.  Single  cell suspensions  of spleens 
and lymph nodes from BALB/c mice were prepared and 1 x  10  s 
cells/ml were diluted in PBS containing 2.5%  FCS and 3 mM 
EDTA. For T cell enrichment negative selecting  columns (MTCC- 
1000; R&D Systems, Minneapolis, MN) were used following the 
instructions of the manufacturer. Human PBL were obtained from 
normal donors by leukapheresis  and purified  on Ficoll-Hypaque  gra- 
dients. For depletion of adherent cells, human PBL were subjected 
to plastic adherence for 2 h at 37~  In some experiments, T cells 
were activated with 1 #g/ml PHA and cultured for >10 d in the 
presence of recombinant tL-2 at 10 U/ml. Greater than 98% of 
these cells expressed CD3 +/CD4 § or CD3 §  § phenotypes 
as detected by indirect immunofluorescence analysis (data not 
shown). 
Proliferation Assay.  50,000  Balb/c splenocytes  were stimulated 
in 200/~1 of culture media with 0.5 #g/ml anti-CD3 or 1/~g/ml 
anti-CD28 mAb. At time 0 and 9 h, cells were pulsed with dia- 
lyzed acidic SMase from human placenta (Sigma Chemical Co.). 
A-SMase was dialyzed for 18 h at 4~  against PBS. Thereafter the 
enzyme activity  was quantified  against standard, nondialyzed  SMase 
activity. At day 3, cells were pulsed for 8 h with [3Hlthymidine 
(1/~Ci/well). Cells were harvested and the amount of [3H]thymi- 
dine incorporated was measured using a B-counter. 
Sphingorayelinase Assays.  Acidic  and neutral sphingomyelinase 
were assayed as recently described (41). Briefly, cells were serum 
starved for 2 h in culture medium supplemented with 2% BSA. 
Aliquots of 5  x  106 cells were treated at 37~  for the indicated 
times with mAb anti-CD28, anti-CD2, or anti-CD3 premix~ with 
cross-linking Ab by incubation for 15 rain on ice. The final con- 
centration each of anti-CD28, anti-CD2, or anti-CD3 was 2/zg/ml 
and that ofcross-llnking  Abs was 8 #g/ml. Stimulation  was stopped 
by immersion of samples in methanol/dry ice (- 70~  for 10 s 
followed  by a 15-s centrifugation in a microfuge. Cells were lysed 
in two distinct buffer systems as described (41). The protein con- 
tent of the supernatants was measured using a bicinchoninic acid 
assay (Pierce Chemical  Co., Hamburg, Germany)  with BSA as stan- 
dard. Equal amounts of protein (between 15 and 50/~g) from cel- 
lular lysates were added to 52.25/~1 of reaction buffer containing 
250 mM sodium acetate, 1 mM EDTA (pH 5.0) for A-SMase mea- 
surements. For N-SMase assays, the buffer contained 20 mM Hepes 
(pH 7.4), 10 mM MgClz, 250/xM ATP. [N-methyl-14C]sphin  - 
gomyelin (56 mCi/mmol) was added (1.1/zCi/ml final concentra- 
tion) and the reaction mixtures were incubated at 37~  for 2 h. 
The reactions were stopped by addition of 800/zl CHC13/meth- 
anol (2:1) and  250  #1  H20.  Finally, they were vortexed and 
microfuged at 14,000 rpm for 2 rain. To quantify the sphingo- 
myelinase activity, 200  /~1  of aqueous phase, containing  the 
[l~C]phosphorylcholine released by  the  enzyme,  was  counted 
using a B-counter (Canberra-Packard, Downers Grove, IL). Alter- 
natively, the amount of [14C]phosphorylcholine  produced was ana- 
lyzed by TIC  using  a  solvent system CH3OH/0.5%  NaCI/ 
NH4OH (50:50:1). Phosphorylcholine,  glycerophosphorylcholine, 
acetylcholine, and choline were used as standards. The amount of 
[t4C]phosphorylcholine produced was  visualized by  autoradi- 
ography. 
Mass Measurements of Ceraraide and Sphingomyelin.  The neutral 
lipid cleavage  product of SMases, ceramide, was measured  by char- 
ring densitometry of  TLC plates as recently described  (38). Briefly, 
phospholipids were extracted according to the method described 
by Bligh and Dyer (42). Neutral lipids were separated from phos- 
pholipids in a two-phase methanol-hexane system. For examina- 
tion of ceramide, neutral lipids were separated  by TLC using a sol- 
vent system of CH3C1/CH3OH/7  N NH4OH/HzO (85:15:0.5: 
0.5). After chromatographic separation of lipids, TLC plates were 
dried and cooled down to room temperature. Plates were exposed 
for 15 s to a solution of 10% copper sulphate in 8% aqueous phos- 
phoric acid. The lipids were charred by heating the TLC plate for 
10 min at 175~  Densitometry of charred bands was performed 
by two-dimensional laser scanning (Personal Densitometer with 
ImageQuant 3.22; Molecular Dynamics, Krefeld, Germany). Cal- 
culations of total masses were performed by use of an exogenous 
ceramide standard (Sigma Chemical Co.). Sphingomyelin  was ex- 
tracted with the phospholipid fraction and analyzed  by TLC using 
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20:5). Sphingomyelin, phosphatidylcholine,  phosphatidic acid, phos- 
phoinositol, phosphoethanol, and lysophosphatidylcholine (Sigma 
Chemical Co.) were used as standards  and visualized by charring 
densitometry. For quantification of sphingomyelin, charred TIC 
plates  were scanned  by two-dimensional laser densitometry. 
ElectroFhoretic Mobility Shift Assay.  Nuclear extracts were pre- 
pared as recently described (39).  The protein concentration was 
measured using a bicinchoninic assay (Pierce Chemical Co.) with 
BSA as standard. The NF-KB-specific oligonucleotide, containing 
the two tandemly arranged NF-KB-binding sites of the HIV-1 long 
terminal repeat enhancer (5'-ATCAGGGACTTTCCGCTGGGG- 
ACTTTCCG-3') and its complementary oligonucleotide was syn- 
thesized on a DNA synthesizer 381A (Applied Biosystems, Weiter- 
stadt,  Germany).  The oligo  was  end  labeled  with  [3,-32p]ATP 
(Amersham International) using T4 polynucleotide kinase (Boeh- 
ringer Mannheim, Mannheim, Germany) and annealed to a 10-fold 
excess of its complementary strand to obtain an end-labeled double- 
stranded oligonucleotide probe. 
Electrophoretic mobility  shift  assays were performed by in- 
cubating 6/~g of nuclear extract with 4 #g of poly(dI-dC) (Phar- 
macia, Freiburg, Germany) in a binding buffer (5 mM Hepes [pH 
7.8], 5 mM MgC12, 50 mM KC1, 0.5 mM dithiothreitol, and 10% 
glycerol [20/~1 final vol  D for 20 rain at room temperature. The 
end-labeled  double-stranded oligonucleotide probe (1  x  10  ~ to 5 
x  104 cpm) was  then added, and the reaction mixture was in- 
cubated for 7 min at room temperature. The samples were sepa- 
rated by native polyacrylamide gel electrophoresis in  low ionic 
strength buffer (0.25x  Tris-borate-EDTA). 
Plasmids, Transfections, and CAT Assays.  A 4x KB HIWIg-CAT 
reporter plasmid containing four tandemly arranged NF-IcB  binding 
sites of the HIWIg enhancer linked to the CAT gene (43) was kindly 
provided by Dr. R. Schmid (Ulm, Germany). The reporter plasmid 
was used to measure functionally NF-KB activation in Jurkat ceUs 
cotransfected with a human acidic  sphingomyelinase expression 
plasmid pHASMase. To generate pHASMase, the full-length cDNA 
for human A-SMase (44, kindly provided by Dr. K. Sandhoff) was 
cloned in both orientations into the high level mammalian expres- 
sion plasmid pEF-BOS (45, kindly provided Dr. S. Nagata). Jurkat 
cells were transfected using by DEAE-dextran with 2.5 #g of the 
4x lob HIWIg-chloramphenicol acetyltransferase  (CAT) plasmid 
and increasing  amounts of A-SMase expression plasmid.  The na- 
tive pEF-BOS plasmid was used to keep a total amount of 5 #g 
DNA transfected. After transfection, cells were grown for 2 h at 
37~  in culture medium. Cells were then left either untreated or 
treated with PMA (20 ng/ml) for 4 h. The actual CAT activities 
were measured in crude cellular extracts using [14C]chloramphen- 
ico] (Amersham International) as substrate followed by TIC to sep- 
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Figure  1.  CD28 crosslinking activates  acidic  SMase in 
human T cells. Triplicates  of 1 x  107/ml primary resting 
T cells (A and B), 10-d PHA-stimuhted T cells (C and 
D), or Jurkat T cells (E and F) were left either untreated, 
or were stimulated by CD28 cross-linking (O), or treated 
with  100 ng/ml recombinant TNF (O).  (A) Human 
resting T cells were treated with anti-CD28 alone (2 
#g/ml) (A) or incubated  with the secondary  cross-linking 
Ab ([2]). Cellular lysates were prepared as described in 
Materials and Methods and acidic  SMase  and neutral  SMase 
were measured using radiolabeled [t4C]sphingomyelin. 
The increase in SMase activity is estimated from the 
amount of radioactive  phosphorylcholine  released (100% 
= amount released at time 0). Basal levels of [14C]phos- 
phorylcholine production were (nag  -1 protein  x  h-t): 
2.5 nmol (A), 207 pmol (/3), 3.33 nmol (C), 195 pmol 
(D), 2.34 nmol (E), and 180 pmol (F). The bars indicate 
SEM (n ;~3). arate  the  native  and  acetylated  forms,  as  described  (46). For 
quantification, autoradiographs were analyzed by two-dimensional 
laser scanning. 
Results 
Activation  of A-SMase  by  CD28  Cross-linking.  Human 
resting peripheral  T  cells were stimulated with  anti-CD28 
antibodies  in the presence or absence of secondary cross-linking 
antibodies and assayed for acidic and neutral SMase activities 
using  exogenous radiolabeled  sphingomyelin  in  a miceUar 
system as recently described (41). As shown in Fig. 1 A, CD28 
cross-linking by anti-mouse IgG antibodies resulted in the 
rapid  induction  of  acidic  SMase  activity.  Increments  of 
A-SMase activity were detected as early as within 30 s and 
peaked at 3 min.  In contrast,  neither anti-CD28  alone nor 
secondary  anti-mouse  IgG  enhanced  A-SMase  activity. 
Notably, CD28  cross-linking  failed to  activate the neutral 
SMase (Fig.  1 B). Similar kinetics of A-SMase activation were 
obtained with CD28-cross-linked primary splenic T cells de- 
rived from Balb/C mice  (data  not  shown). 
Since PI-3 kinase activation seems to depend on the extent 
of CD28 phosphorylation, that is, on the state of T cell acti- 
vation, we next investigated the effects of CD28 cross-linking 
on A-SMase activity in PHA-stimulated cultured human pe- 
ripheral T  cells. As shown in Fig.  1 C, CD28 cross-linking 
of preactivated  human  T  cells  stimulated  the activation  of 
A-SMase. Notably, the amplitude of A-SMase activation was 
reproducibly found to be reduced when  compared to that 
obtained with TNF or that observed with CD28-cross-linked 
resting T cells. Unlike TNF, CD28 failed to induce the acti- 
vation  of neutral  SMase  (Fig.  1 D). 
The Jurkat leukemic T  cell line has been extensively used 
for studying CD28 signaling. Jurkat T cells were treated with 
anti-CD28 and acidic as well as neutral SMase activities were 
measured.  As shown in Fig.  1 E, CD28 cross-linking leads 
to  the activation  of the A-SMase.  The transient  activation 
of A-SMase by CD28 peaked between 2 and 3 min after cross- 
linking,  which parallels  the kinetics observed with primary 
human T  cells.  In addition,  both amplitude and kinetics of 
A-SMase activation  were comparable to the levels induced 
by TNF. N-SMase activation  was not detected in CD28-cross- 
linkedJurkat T cells (Fig. 1 F). These data establish that CD28 
can trigger  acidic  but not neutral  SMase in resting  T  cells 
as well as in  PHA-activated T  cells  or leukemic T  cells. 
To confirm A-SMase activation by CD28,  water-soluble 
reaction products of the in vitro micellar assay system were 
analyzed by TLC.  As shown in Fig.  2, CD28 cross-linking 
elicited  an  enzymatic  activity  that  exclusively  produced 
[14C]phosphorylcholine  identified by a parallel reaction using 
exogenous bacterial  SMase.  [14C]choline  was not  detected, 
which argues against  any phospholipase D activity that might 
have contributed to SM hydrolysis in the micellar assay system. 
Furthermore, when mass measurements of ceramide were per- 
formed with  anti-CD28-stimulated  Jurkat  T  cells,  a time- 
dependent increase of cellular ceramide was detected, which 
stoichiometrically corresponded to a concomitant breakdown 
of sphingomyelin  (Fig.  3). 
Figure  2.  A-SMase  activity in CD28-cross-linked  Jurkat T cells ana- 
lyzed by TLC. (A) Jurkat T cells were stimulated in triplicates by CD28 
cross-linking. At the indicated times, cellular lysates were prepared and 
incubated with [14C]sphingomyelin  for 2 h. The aqueous phase was ex- 
tracted and analyzed by TLC. In a parallel reaction [14C]sphingomyelin 
was hydrolyzed  by bacterial SMase to produce a radioactive  phosphoryl- 
choline standard ([14C]Pchol, arrow). The [14C]phosphorylcholine  pro- 
duced was visualized  by autoradiography. (B) The bands of  (A) representing 
the amount of [14C]Pchol  produced were quantitated by two-dimensional 
laser densitometer scanning. The bars indicate SEM (n  =  3). 
Finally,  Jurkat  T  cells  were  preincubated  for  1  h  with 
the  endolysomotropic  agents  monensin,  chloroquine,  and 
NH4C1. These agents have been shown to be inhibitory  to 
the activation of the A-SMase following TNF  stimulation 
(41),  leaving the N-SMase unaffected. As shown in Fig.  4, 
each of the endolysomotropic agents  completely abolished 
the  activation  of A-SMase  by  CD28  crosslinking.  These 
findings therefore strongly support that CD28 cross-linking 
results in exclusive activation of A-SMase without  engage- 
ment  of the  neutral  sphingomyelinase  pathway. 
One of the most prominent  effects of CD28 is to syner- 
gize with the TCR to optimally activate T  cells. Strikingly, 
cross-linking  of either CD3 or CD2 did not result in A-SMase 
activation  (Fig.  5).  Thus,  the  A-SMase  may  represent  a 
costimulatory pathway, by which CD28 complements  sig- 
naling through the TCR complex. To examine whether CD28 
costimulation  can be substituted for by exogenous SMase, 
mouse splenocytes were pulsed at 0 and at 9 h with increasing 
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Figure  3.  SMase  activity  in CD28-cross-linkedJurkat  T cells analyzed 
by mass measurements  of ceramide  and sphingomyelin.  Jurkat T cells  were 
stimulated in triplicates  by CD28 cross-linking. At the indicated  times, 
neutral lipids and phospholipids were extracted and separated by TIC. 
To visualize  neutral lipids and phospholipids, TIC plates were charred. 
For quantification,  the charred  bands were read  by two-dimensional  laser 
densitometry. Calculations  of total masses were performed  using exoge- 
nous ceramide and sphingomyelin  as standards. The bars indicate SEM 
(n  =  3). 
concentrations of A-SMase from human placenta (Fig.  6). 
Exogenous A-SMase synergized with CD3 cross-linking to 
induce a dose-dependent proliferative response,  which was 
comparable to that observed with cells treated with a combi- 
nation of anti-CD3 and anti-CD28 mAb. Cells not exposed 
to any mAb and cells stimulated with anti-CD28 alone re- 
mained in a resting state, ruling out non-specific  mitogenic 
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Figure 4.  CD28-dependent  activation  of acidic SMase is inhibited  by 
endolysomotropic  agents. Jurkat cells were incubated for 1 h in the ab- 
sence (0) or presence of either monensin (10/tg/ml) (A), chloroquine 
(2 raM) (I-3), or NH4CI (100 raM) (~). Notably,  chloroquine  diminished 
the basal A-SMase  activity  by 45%. Cells were then left either untreated 
or stimulated  by CD28 cross-linking.  Acidic  SMase activities  were mea- 
sured. Bars indicate SEM (n  = 3). 
effects of the SMase treatment. In addition, heat-inactivated 
A-SMase did not induce cell proliferation (data not shown), 
indicating the requirement for enzymatic activity. At con- 
centrations >7/~g/ml exogenous A-SMase  appeared  to be 
cytotoxic. 
Overexpression of  Recombinant A-SMase Substitutes  for CD28 
Costimulatory Signals.  On a molecular basis, TCR and CD28 
costimulatory signaling has been shown to converge at the 
NF-rB (35, 47), which eventually precipitates  in an increase 
of IL-2 production, IL-2 receptor expression,  and enhance- 
ment of T  lymphocyte proliferation. Confirming previous 
reports (35, 47), incubation of mouse primary T  cells with 
either  anti-CD3  or  anti-CD28  alone  did  not  result  in 
significant NF-rB activation (Fig. 7). In contrast, combined 
anti-CD3 and anti-CD28 treatment revealed a strong syner- 
gism. The specificity of the retarded complexes was demon- 
strated by competition analysis with wild-type and mutated 
HIV-rB oligonucleotides (data not shown). No synergism 
of CD3 and CD28 cross-linking was observed  with Jurkat 
T cells (Fig. 7 B). Instead, CD28 cross-linking strongly en- 
hanced phorbol-ester-induced NF-rB activation as previously 
described  (35,  47). 
We next tested whether expression of recombinant human 
A-SMase can substitute for CD28 signaling. Transfection of 
Jurkat T  cells with a human A-SMase  expression  plasmid, 
pHASMase (Fig.  8 A), resulted in elevated nuclear NF-rB 
activity (Fig.  7  C).  The  kinetics  of pHASMase-directed 
A-SMase activities in Jurkat T cells presented in Fig. 8 B in- 
dicated that recombinant A-SMase was active within the first 
hour after transfection. Two-dimensional laser scanning re- 
vealed a 1.8-,  2.0-, and 2.1-fold  increase of NF-rB activity 
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Figure  5.  CD3 and CD2 fail to activate A-SMase in resting 
T  cells. Human resting T cells were stimulated in triplicates 
by cross-linking of either CD28 (Q), CD3 (O), or CD2 (A). 
At indicated times cellular lysates were prepared and analyzed 
for A-SMase activity. The bars  indicate SEM (n  =  3). 
at 1 h, 2 h, or 4 h after transfection, respectively (data not 
shown).  This suggests that A-SMase on its own can func- 
tion as a weak activator of NF-xB. A control plasmid, pHAS- 
Mase  ....  containing the A-SMase cDNA in opposite orien- 
tation,  did not change NF-KB activity. 
To  address functionally the costimulatory potential  of 
A-SMase, pHASMase and an NF-KB-CAT reporter plasmid 
were cotransfected into Jurkat T cells. As shown in Fig. 9, 
A-SMase dose-dependently enhanced transcription from the 
HIWIg-KB element. In addition, A-SMase cooperated with 
PMA-induced NF-KB activation, which corresponds  well with 
the synergistic effects of CD28 and PMA on nuclear translo- 
cation of NF-KB (Fig. 7). In contrast,  CD28 cross-linking 
alone did not result in NF-~B activation, nor did it synergize 
with the overexpressed A-SMase. CD28 ligation slightly in- 
creased PMA-induced NF-KB activation, which is likely due 
to a presumably higher frequency of CD28-cross-linked cells 
compared to the fraction of cells successfully  transfected with 
the pHASMase plasmid. 
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Fignre  6.  Cellular response  to exogenous A-SMase. Triplicates of mouse 
spleen cell cultures were left untreated or stimulated for 3 d with anti- 
CD3 (0.5/xg/ml) or anti-CD28 (1/~g/ml).  Cells were pulsed at time 0 
and 9 h with A-SMase at the indicated concentrations. The rate of prolifer- 
ation was measured by [3H]thymidine incorporation.  The bars represent 
SEM (n  =  3).  The results  are representative for three independent  ex- 
periments. 
Discussion 
CD28 engagement has been shown to have  potentially great 
impact on the generation of an appropriate adaptive immune 
response (1, 2). This crucial interdependence  between the TCR 
and CD28 may represent one possible mechanism for periph- 
eral immune tolerance. Here we show that CD28 can induce 
rapid and transient activation of the acidic sphingomyelinase 
pathway in primary T cells. Because CD3 triggering did not 
elicit any ceramide production by A-SMase, this lipid mes- 
senger  system can be viewed as  a  distinct  costimulatory 
pathway. 
Lipid second messenger systems are emerging as impor- 
tant signaling components in a variety of cellular systems. 
One possible entry for A-SMase action in T cell activation 
likely resides in the activation of the nuclear transcription 
factor NF-KB. This notion is confirmed by our observation 
that overexpression  of recombinant A-SMase  mimicked CD28 
effects on NF-KB activation in Jurkat T  cells. NF-xB con- 
trols the expression of a number of genes involved in T cell 
activation. In particular, NF-xB has been shown to regulate 
the expression of the genes encoding IL-2 and IL-2 recep- 
tor-or chain that are instrumental for T cell proliferation. This 
suggests that A-SMase  represents a major mediator of  CD28- 
induced T cell proliferation. The mitogenic effects of exoge- 
2064  CD28  Signals through  Acidic Sphingomyelinase Figure 7.  Costimulator effects of CD28 and A-SMase  on 
NF-~B activation in mouse peripheral T cells and Jurkat T 
cells. Mouse peripheral T cells (.4) or Jurkat T cells (B) were 
left untreated or treated for 8 h in the presence of anti-CD28 
(1 #g/ml) and/or anti-CD3 (0.5 #g/ml) or PMA (5 ng/ml) 
at 37~  (C) Jurkat T  cells were transfected for indicated 
periods of time with A-SMase cDNA cloned into pEF-BOS 
in both orientations  (see Fig. 8 A). Nuclear proteins  were 
extracted and assayed for NF-KB activity. 
Figure 8.  Expression of human A-SMase cDNA in Jurkat T cells. (A) The cDNA for human A-SMase (44) was cloned in both orientations  into 
the expression plasmid pEF-BOS (45) to generate pHASMase and pHASMase  .... respectively. (B) Jurkat T cells were transfected in triplicates with 
5/~g of either pHASMase or pHASMase  .... At the indicated times, cellular lysates were prepared and analyzed for A-SMase activity. The bars indicate 
SEM (n  =  3). 
2065  Boucher et al. Figure 9.  Overexpression  of acidic SMase in Jurkat cells leads to acti- 
vation of NF-KB.  Jurkat T cells were cotransfected with 2.5 ttg of HIWIg- 
xB-CAT reporter construct along with increasing concentrations of pHAS- 
Masc. After 2 h, cells were left either untreated (Open bars) or stimulated 
for 4 h at 37~  with PMA (20 ng/ml, gray  Mrs), CD28  cross-linking 
(hatched bars), or a combination of PMA and CD28 cross-linking (filled 
bars). CAT activity of crude cellular extracts was measured using radiola- 
beled chloramphenicol. The results shown are derived from one represen- 
tative experiment (n  =  4). 
nous A-SMase in the presence of anti-CD3 mAb (Fig. 6) appear 
to confirm the costimulatory nature of endosomal A-SMase 
activation by CD28 cross-linking. We wish to emphasize, 
however, that this interpretation deserves a precaution. Sphin- 
gomyelin (SM) is asymmetrically distributed in the plasma 
membrane: >95% of SM is found at the outer leaflet of the 
plasma membrane (48). Exogenous SMase treatment may thus 
cause extensive SM hydrolysis leading to membrane damage. 
This notion is illustrated by the cytotoxicity produced by 
A-SMase used at high concentrations (Fig. 6). Furthermore, 
SMases are also known as bacterial  toxins like hemolysins, 
which destroy eukaryotic membranes (49). Thus, it cannot 
be excluded that the mitogenic effects of exogenous A-SMase 
may be secondary, at least in part, to a cellular stress response. 
Notwithstanding, expression of recombinant A-SMase clearly 
activated transcription from a NF-~B promoter. The internal 
treatment with A-SMase, which more closely resembles en- 
dogenous  A-SMase  action,  suggested  that  A-SMase  can 
mediate CD28-induced T  cell activation and proliferation 
through activation of NF-xB. 
A  number of different types of CD28-dependent signal 
transfer reactions have been described. However, the specific 
signaling pathways complementing TCR function have not 
yet been identified. Costimulation by CD28 may be brought 
about by several pathways:  (a) CD28 ligation may provide 
additional, distinct signaling systems like A-SMase; (b) CD28 
may enhance the amplitude or duration of a TCR-triggered 
signal, thereby reaching a threshold to activate further down- 
stream signaling cascades; and (c) CD28 may provide signals 
similar to the TCR complex  yet at different time points. This 
may result in repetitive stimulation required to maintain a 
proliferative or functional activation status. Unlike A-SMase, 
other signaling pathways ascribed to CD28 appear to be also 
engaged by the TCK. For example, PI 3-kinase is also cou- 
pled to TCR signaling through tyrosine kinases, such as lck 
(50). Further, PI-C3,1 and raf-1 kinase are inducible by cross- 
linking of either CD28 or TCR (28, 29). Given that the TCR 
and CD28 obviously share quite a number of signaling cas- 
cades,  synergistic  effects  may  involve  any  of  the  above- 
mentioned cooperative pathways. The activation of A-SMase 
may be essential  to maintain some degree of specificity of 
the CD28 signal.  It is important to emphasize that CD28 
ligation led to A-SMase activation in resting T lymphocytes 
as well as in T cell blasts or transformed  Jurkat T cells. Thus, 
A-SMase activation occurs independent of the T cell activa- 
tion status. This is in contrast to the activation of PI 3-kinase, 
which requires  TCR-induced phosphorylation of the cyto- 
plasmic tail  of CD28 at residue Tyr  191 (26,  27). 
Interestingly, CD28 cross-linking did not result in activa- 
tion of neutral sphingomyelinase.  Neutral sphingomyelinase 
has been implicated in activation of phospholipase A2 and 
arachidonic acid degradation (41). Arachidonic acid metabo- 
lites, such as leukotrienes or prostaglandins, have extensively 
been implicated in cytotoxicity and inflammatory processes. 
Proinflammatory cytokines like TNF and IL-1 activate both 
acidic and neutral sphingomyelinase (41). The stimulation 
of A-SMase in the absence of neutral sphingomyelinase acti- 
vation is thus a property of CD28, which distinguishes this 
costimulatory  molecule  from  cell  surface  receptors  for 
proinflammatory cytokines. 
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